Abstracts tagged "non-radiographic and spondylarthritis"

Abstract Number: 312 • 2018 ACR/ARHP Annual Meeting
Diagnostic Value of MRI in Non-Radiographic Axial Spondyloarthritis
Tamara Rusman¹, Marie-Luise John², Mignon van der Weijden², Bouke Boden³, Joyce van der Bijl², Stefan Bruijnen⁴, Conny van der Laken⁵, Michael T. Nurmohamed⁶ and Irene van der Horst-Bruinsma⁷, ¹Rheumatology, VU University medical centre, Amsterdam, Netherlands, ²Amsterdam Rheumatology immunology Center |Department of Rheumatology VU University Medical Center, Amsterdam, Netherlands, ³Radiology, VU University Medical Center, Amsterdam, Netherlands, ⁴Dept. of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, ⁶Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Few studies showed signs of inflammation at the MRI of the sacroiliac joints (SIJ) or spine in only 30% of the non-radiographic axial spondyloarthritis…
Abstract Number: 1506 • 2017 ACR/ARHP Annual Meeting
Similarities and Differences between Patients Fulfilling Non-Radiographic Axial Spondyloarthritis and Undifferentiated Spondyloarthritis Criteria: Results from the Esperanza Cohort
Antonio Juan¹, Xavier Juanola², Eugenio De Miguel³, Eduardo Collantes-Estevez⁴, Juan Carlos Quevedo⁵, Elena Alonso⁶ and Victoria Navarro-Compán⁷, ¹Hospital Universitario Son Llàtzer. Rheumatology, Palma de Mallorca, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ⁴Rheumatology, IMIBIC-Hospital Universitario Reina Sofia, Cordoba, Spain, ⁵H. Universitario de Gran Canaria Dr. Negrín., Las Palmas., Spain, ⁶Hospital Universitario Virgen del Rocío, A Curuña, Spain, ⁷Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Traditionally, patients with spondyloarthritis (SpA) were classified in five subgroups: ankylosing spondylitis (AS), psoriatic arthritis, arthritis associated with inflammatory bowel disease, reactive arthritis and…
Abstract Number: 1513 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Atul A. Deodhar¹, Theresa Hunter², David Sandoval Calderon³, Steve Lobosco⁴, Rachel Moon⁴ and Gary Milligan⁵, ¹Oregon Health & Science University, Portland, OR, ²Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: Timely identification of nr-axSpA may lead to earlier intervention to reduce symptoms, improve function, and reduce disease burden. The purpose of this study was…
Abstract Number: 1520 • 2017 ACR/ARHP Annual Meeting
Golimumab Retention Rate in Patients with Spondyloarthitis. Differences between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Belen Serrano¹, Carlos M Gonzalez², Roberto González³, Julia Martínez-Barrio⁴, Juan Gabriel Ovalles-Bonilla⁵, Juan Carlos Nieto², Iustina Janta², Larissa Valor³, Francisco Javier López Longo⁶ and Indalecio Monteagudo², ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The efficacy of Golimumab (GLM) treatment in spondyloarthritis (SpA) has been widely documented. The aim of this study was to analize the long-term retention…
Abstract Number: 1534 • 2017 ACR/ARHP Annual Meeting
Comparison of Long Term Anti-Tnf Survival in Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis; Data from Turkbio Registry
Gercek Can¹, Ediz Dalkılıc², Yavuz Pehlivan², Soner Senel³, Servet Akar⁴, Dilek Solmaz⁵, Suleyman Serdar Koca⁶, Nevsun İnanc⁷, Pamir Atagunduz⁷, Ayten Yazıcı⁸, Ayse Cefle⁸, Berna Goker⁹, Berrin Zengin¹, Sadettin Uslu¹⁰, Nurullah Akkoc¹¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Rheumatology, Uludag University Faculty of Medicine Rheumatology, bursa, Turkey, ³Rheumatology, Erciyes University Faculty of Medicine Rheumatology, kayseri, Turkey, ⁴Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, izmir, Turkey, ⁶Rheumatology, Fırat University Faculty of Medicine, elazıg, Turkey, ⁷Rheumatology, Marmara University Faculty of Medicine Rheumatology, istanbul, Turkey, ⁸Rheumatology, Kocaeli University Faculty of Medicine Rheumatology, kocaeli, Turkey, ⁹Rheumatology, Gazi Universty of Fakulty of Medicine, ankara, Turkey, ¹⁰Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ¹¹Rheumatology, Private Practice, Rheumatology, İzmir, Turkey
Background/Purpose: Limited data are available on anti-TNF survival in non-radiographic axial spondyloarthritis (nr-axSpA) patients and their long-term survival in ankylosing spondylitis (AS). The aim of…
Abstract Number: 1736 • 2016 ACR/ARHP Annual Meeting
Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study
Celine Vidal¹, Cédric Lukas², Bernard Combe³, Francis Berenbaum⁴, Christian Jorgensen⁵, Jeremie Sellam⁶ and Jacques Morel⁷, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ³Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁴Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁵Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, ⁶Rheumatology, Saint-Antoine Hospital, Paris, France, ⁷Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France
Background/Purpose: TNF inhibitors (TNFi) are effective treatment in radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA). Nr-axSpA have lower response rate in case of absence…
Abstract Number: 2604 • 2014 ACR/ARHP Annual Meeting
Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis : the Same Syndrome or Different Diseases? Analysis from Esperanza Cohort
Azucena Hernández-Sanz¹, Victoria Navarro-Compán², Cristina Fernández-Carballido³, Carlos Montilla-Morales⁴, Juan Mulero⁵ and Eugenio De Miguel⁶, ¹H. Virgen de la Salud, Toledo, Spain, ²Rheumatology, University Hospital La Paz, Madrid, Spain, ³Rheumatology, University General Hospital Elda, Elda (Alicante), Spain, ⁴H. de Salamanca, Salamanca, Spain, ⁵Rheumatology, University Hospital Puerta de Hierro, Majadahonda (Madrid), Spain, ⁶Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose New ASAS criteria for axial spondyloarthritis (axSpA) have two entrances: the imaging and clinical arm (presence of HLA B27). The imaging arm allows classifying patients…
Abstract Number: 2612 • 2014 ACR/ARHP Annual Meeting
Different Performance of the Major Disease Activity Measures ASDAS and Basdai in Patients with Axial Spondyloarthritis Treated with Non-Steroidal Anti-Inflammatory Agents – Results from a Prospective Study
Xenofon Baraliakos¹, Uta Kiltz¹, Frank Heldmann¹, Heiner Appel², Friedrich Dybowski³, Manfred Igelmann⁴, Ludwig Kalthoff⁵, Dietmar Krause⁶, Hans-Jürgen Menne⁷, Ertan Saracbasi⁸, Elmar Schmitz-Bortz⁹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology and Nephrology Practice, Hamm, Germany, ³Rheumatology Practice, Herne, Germany, ⁴Rheumatology Practice, Bochum, Germany, ⁵Rheumatology practice, Herne, Germany, ⁶Rheumatology practice, Gladbeck, Germany, ⁷Rheumatology practice, Dortmund, Germany, ⁸Rheumatology practice, Oberhausen, Germany, ⁹Rheumatology practice, Hattingen, Germany
Background/Purpose: The ASAS/EULAR recommendations for the management of patients (pts) with axial spondyloarthritis (axSpA) have established non-steroidal anti-inflammatory agents (NSAIDs) as first choice of medical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].